2024 | Xiaoxiao Hu, Mo Zhang, Cuilu Quan, Saisai Ren, Wei Chen, Jing Wang
This study presents a novel ROS-responsive and triple-synergistic mitochondria-targeted polymer micelle (CTC) for efficient induction of Immunogenic Cell Death (ICD) in tumor therapeutics. The CTC micelle is designed to target mitochondria, stimulate reactive oxygen species (ROS) production, and enhance photodynamic therapy (PDT) and chemotherapy. The micelle consists of two main components: CPT-CA-PEG-TPP, which stimulates ROS production and targets mitochondria, and PEG-Ce6, which generates ROS upon laser irradiation. The encapsulation of catalase (CAT) within the micelles further enhances ROS generation and oxygen production. In vitro studies demonstrate that the CTC micelle effectively induces ICD, releases calreticulin (CRT), and activates the release of high mobility group box 1 (HMGB1) and adenosine triphosphate (ATP). Animal trials show that the CTC micelle, administered via tail vein injection, efficiently induces ICD and inhibits tumor growth after laser irradiation. Transcriptome analysis reveals changes in the tumor genome induced by the CTC micelle. This work highlights a novel strategy for improving combination immunotherapy using nanotechnology.This study presents a novel ROS-responsive and triple-synergistic mitochondria-targeted polymer micelle (CTC) for efficient induction of Immunogenic Cell Death (ICD) in tumor therapeutics. The CTC micelle is designed to target mitochondria, stimulate reactive oxygen species (ROS) production, and enhance photodynamic therapy (PDT) and chemotherapy. The micelle consists of two main components: CPT-CA-PEG-TPP, which stimulates ROS production and targets mitochondria, and PEG-Ce6, which generates ROS upon laser irradiation. The encapsulation of catalase (CAT) within the micelles further enhances ROS generation and oxygen production. In vitro studies demonstrate that the CTC micelle effectively induces ICD, releases calreticulin (CRT), and activates the release of high mobility group box 1 (HMGB1) and adenosine triphosphate (ATP). Animal trials show that the CTC micelle, administered via tail vein injection, efficiently induces ICD and inhibits tumor growth after laser irradiation. Transcriptome analysis reveals changes in the tumor genome induced by the CTC micelle. This work highlights a novel strategy for improving combination immunotherapy using nanotechnology.
[slides] ROS-responsive and triple-synergistic mitochondria-targeted polymer micelles for efficient induction of ICD in tumor therapeutics | StudySpace